晚期非小细胞肺癌患者的预后因素:患者特征和化疗类型。

Lung cancer international Pub Date : 2011-01-01 Epub Date: 2010-12-05 DOI:10.4061/2011/152125
Salah Abbasi, Ahmed Badheeb
{"title":"晚期非小细胞肺癌患者的预后因素:患者特征和化疗类型。","authors":"Salah Abbasi,&nbsp;Ahmed Badheeb","doi":"10.4061/2011/152125","DOIUrl":null,"url":null,"abstract":"<p><p>Eleven prognostic factors were retrospectively analyzed in 270 newly diagnosed patients with advanced non-small-cell lung cancer including age, sex, performance status, histology, stage, smoking status, hemoglobin level, forced expiratory volume in one second (FEV1), weight loss >5% in 3 months preceding therapy, number of involved organs, and type of first-line chemotherapy. Response rate was 35.6%, and median survival was 8.2 months (95% CI, 7.8 to 8.7) for the whole group. Age ≤60 years (P = .016), FEV1 ≥ 2L (P = .03), and the use of platinum/docetaxel (P < .0001) were significantly associated with an improved survival. Histology did not affect outcome in the absence of targeted therapies. </p>","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2011 ","pages":"152125"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4061/2011/152125","citationCount":"32","resultStr":"{\"title\":\"Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.\",\"authors\":\"Salah Abbasi,&nbsp;Ahmed Badheeb\",\"doi\":\"10.4061/2011/152125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Eleven prognostic factors were retrospectively analyzed in 270 newly diagnosed patients with advanced non-small-cell lung cancer including age, sex, performance status, histology, stage, smoking status, hemoglobin level, forced expiratory volume in one second (FEV1), weight loss >5% in 3 months preceding therapy, number of involved organs, and type of first-line chemotherapy. Response rate was 35.6%, and median survival was 8.2 months (95% CI, 7.8 to 8.7) for the whole group. Age ≤60 years (P = .016), FEV1 ≥ 2L (P = .03), and the use of platinum/docetaxel (P < .0001) were significantly associated with an improved survival. Histology did not affect outcome in the absence of targeted therapies. </p>\",\"PeriodicalId\":91139,\"journal\":{\"name\":\"Lung cancer international\",\"volume\":\"2011 \",\"pages\":\"152125\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4061/2011/152125\",\"citationCount\":\"32\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung cancer international\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4061/2011/152125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2010/12/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung cancer international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4061/2011/152125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2010/12/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 32

摘要

回顾性分析270例新诊断晚期非小细胞肺癌患者的11个预后因素,包括年龄、性别、运动状态、组织学、分期、吸烟状况、血红蛋白水平、1秒用力呼气量(FEV1)、治疗前3个月体重减轻>5%、受累器官数量、一线化疗类型等。全组有效率为35.6%,中位生存期为8.2个月(95% CI, 7.8 ~ 8.7)。年龄≤60岁(P = 0.016)、FEV1≥2L (P = 0.03)和使用铂/多西他赛(P < 0.0001)与生存率的提高显著相关。在没有靶向治疗的情况下,组织学不影响结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.

Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.

Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.

Eleven prognostic factors were retrospectively analyzed in 270 newly diagnosed patients with advanced non-small-cell lung cancer including age, sex, performance status, histology, stage, smoking status, hemoglobin level, forced expiratory volume in one second (FEV1), weight loss >5% in 3 months preceding therapy, number of involved organs, and type of first-line chemotherapy. Response rate was 35.6%, and median survival was 8.2 months (95% CI, 7.8 to 8.7) for the whole group. Age ≤60 years (P = .016), FEV1 ≥ 2L (P = .03), and the use of platinum/docetaxel (P < .0001) were significantly associated with an improved survival. Histology did not affect outcome in the absence of targeted therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信